Prior to joining Savient Pharma, Johnson worked as the senior vice president of Eli Lilly and the president of Lilly Oncology Business Unit.
Before Eli Lilly, he has served as the CEO of a developer of targeted biologic cancer treatments, ImClone Systems.
Johnson said he look forward to working with the dedicated and talented Savient employees to bring relief to those adult patients suffering from chronic gout refractory to conventional therapy.
"My focus will be on successfully launching Krystexxa globally in order to build value for all our stakeholders," Johnson said.